Evidence map›Paper›PMID 33381922›Full record

ArticleCancer medicine2021

Circulating CEA-positive and EpCAM-negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer.

Yuichiro Miki, Masakazu Yashiro, Kenji Kuroda, Tomohisa Okuno, Shingo Togano, Go Masuda, Hiroaki Kasashima, Masaichi Ohira

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Circulating tumor cells: biology and clinical significance.Signal transduction and targeted therapy · 2021
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yuichiro MikiDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Masakazu YashiroDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.ORCID 0000-0001-5743-7228
Kenji KurodaDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Tomohisa OkunoDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Shingo ToganoDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Go MasudaDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Hiroaki KasashimaDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Masaichi OhiraDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Osaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been reported that circulating tumor cells (CTCs) are beneficial for predicting tumor stage or treatment response. Although epithelial cell adhesion molecules (EpCAMs) and cytokeratin (CK) have been often used for the identification of CTCs, other tumor markers have not been fully investigated as detecting tools for CTCs. Thus, this study aims to clarify the significance of carcinoembryonic antigen (CEA, CD66e)-positive CTCs in patients with gastric cancer. A total of 150 patients with gastric cancer were enrolled in this study. The mononuclear fraction of peripheral blood was enriched by Ficoll. The number of cells was enumerated depending on the positivity of EpCAM and CEA or CK by flow cytometry. The association of these cells with clinicopathologic characteristics was investigated. The mean age was 70 (range 28-92). The macroscopic type of gastric cancer was classified as 0/1/2/3/4/5 in 59/11/22/38/16/4 patients, respectively. Seventy-one patients (47.3%) were diagnosed with intestinal-type cancer, while 76 patients (50.7%) were diagnosed with the diffuse type. The mean numbers of cells with EpCAM-CK+, EpCAM+CK-, EpCAM+CK+, EpCAM-CEA+, EpCAM+CEA-, and EpCAM+CEA+ were 618, 237, 19.9, 1147, 291, and 7.41, respectively. The number of EpCAM-CEA+cells was significantly higher in patients with stage II-III and IV than in patients with stage I. The 3-year RFS rate in patients with a high number of EpCAM-CEA+cells (>=622) was 57.5%, while it was 79.3% in patients with a low number of EpCAM-CEA+cells (<622) (log-rank p = 0.0079). Thus, we conclude that CEA-positive CTCs will be a clinically beneficial biomarker in patients with gastric cancer.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCarcinoembryonic AntigenEpithelial Cell Adhesion MoleculeFemaleFollow-Up StudiesGastrectomyGPI-Linked ProteinsHumansLymph Node ExcisionMaleMiddle AgedNeoplasm Recurrence, LocalBiomarkers, TumorCarcinoembryonic AntigenCEACAM5 protein, humanEPCAM protein, humanEpithelial Cell Adhesion MoleculeGPI-Linked ProteinsCTCEMTgastric cancer

Identifiers

PMID33381922
PMCPMC7877362
OpenAlexW3114177336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.